Gaudium IVF and Women Health Ltd
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India.[1]
- Market Cap ₹ 520 Cr.
- Current Price ₹ 71.5
- High / Low ₹ 99.8 / 71.2
- Stock P/E 28.3
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 47.8 %
- ROE 51.6 %
- Face Value ₹ 5.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 50.0%
Cons
- Debtor days have increased from 87.3 to 146 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 44 | 46 | 59 | |
| 24 | 27 | 31 | |
| Operating Profit | 20 | 19 | 28 |
| OPM % | 45% | 41% | 48% |
| 0 | 0 | 0 | |
| Interest | 0 | 1 | 2 |
| Depreciation | 1 | 2 | 2 |
| Profit before tax | 18 | 16 | 25 |
| Tax % | 26% | 38% | 25% |
| 13 | 10 | 19 | |
| EPS in Rs | 133.91 | 100.28 | 3.03 |
| Dividend Payout % | 48% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 50% |
| Last Year: | 52% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 31 |
| Reserves | 22 | 26 | 15 |
| 10 | 17 | 21 | |
| 2 | 7 | 9 | |
| Total Liabilities | 35 | 51 | 75 |
| 16 | 18 | 18 | |
| CWIP | 0 | 0 | 7 |
| Investments | 1 | 1 | 6 |
| 18 | 31 | 44 | |
| Total Assets | 35 | 51 | 75 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 24 | 3 | 8 | |
| -14 | -5 | -15 | |
| 4 | -1 | 2 | |
| Net Cash Flow | 13 | -3 | -5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 7 | 108 | 146 |
| Inventory Days | 101 | 141 | 170 |
| Days Payable | 83 | 85 | 99 |
| Cash Conversion Cycle | 26 | 164 | 218 |
| Working Capital Days | -54 | -22 | 46 |
| ROCE % | 44% | 48% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
19 Mar - Q3 revenue ₹2,450.70L, Q3 net ₹363.05L; 9M net ₹1,614.90L; IPO raised ₹16,500.098L; listed Feb 27, 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 19 Mar
-
Announcement under Regulation 30 (LODR)-Change in Management
18 Mar - March 18, 2026: Appointed Ram Rattan & Associates (Internal) and Suresh Nainwal & Co. (Secretarial) for FY2025-26.
-
Board Meeting Outcome for Board Meeting Outcome For Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025
18 Mar - Approved Q3/9M Dec 31, 2025 results; IPO 20,886,200 shares @Rs79 (Rs16,500.098L); listed Feb 27, 2026.
-
Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025
18 Mar - Board approved unaudited Q3 and nine-month results; IPO of 20,886,200 shares at Rs79 raising Rs16,500.098 Lakhs; listed Feb 27, 2026.
Business Profile[1][2]
The company operates in the Assisted Reproductive Technology (ART) and IVF segment in India, following a hub-and-spoke model across 30+ locations (7 hubs and 28 spokes). It also runs a 15-bed day-care hospital in Janakpuri (Delhi NCR) and operates an in-house pharmacy through its wholly owned subsidiary, Gaudium International Pvt. Ltd.